SK Biopharm Unveils 'AI Healthcare Platform' for Epilepsy Patients

Seizure Prediction and Alert Features Unveiled at 'SK AI' Summit
Securing Real-World Data Through Patient Engagement

SK Biopharm announced on the 5th that it showcased its digital healthcare platform under development for managing epilepsy patients' conditions at the 'SK AI Summit' held at COEX, Seoul.

SK Biopharm is showcasing a smart device linked with the epilepsy management AI platform 'Zero' at the 'SK AI Summit' held on the 5th at COEX, Seoul. Photo by SK Biopharm

SK Biopharm's epilepsy patient management platform consists of a mobile application (app), smartwatch, medical staff web service, and an artificial intelligence (AI)-based seizure prediction system. The mobile app for patients and caregivers provides seizure history, seizure statistics, seizure trigger records, and medication history, helping patients and caregivers effectively prepare for seizures through real-time seizure alerts and prediction features. The smartwatch delivers key information such as seizure alerts and predictions in real time, further enhancing patient safety.

For medical staff, the web service shares patients' seizure history, statistics, and medication information in real time, enabling more systematic patient management. AI-based EEG analysis analyzes and predicts the occurrence of epileptic seizures in real time, immediately notifying patients and caregivers while also providing meaningful information to medical staff.

The core of digital healthcare is patients' voluntary data provision and continuous participation. SK Biopharm's epilepsy management platform implements seizure prediction and alert functions, which patients consider most important, expecting a high user retention rate. By expanding opportunities for patients to participate directly and provide data, it continuously generates Real World Data (RWD).

SK Biopharm also expects to secure proprietary Post-Marketing Surveillance (PMS) data for monitoring the efficacy of not only its own drug cenobamate but also other epilepsy medications through this platform. Furthermore, it plans to support communication on the effects and usage experiences of prescribed drugs through a direct communication channel between patients and pharmaceutical companies, building patient-tailored services and management systems based on this.

Lee Dong-hoon, CEO of SK Biopharm, said, "Through innovative healthcare services that combine AI and digital technology, we are preparing new solutions for patients and medical staff, which will serve as an opportunity to further strengthen our competitiveness in the global digital healthcare market." He added, "We will continue to lead in providing better lives for patients through technological advancements."

This content was produced with the assistance of AI translation services.